Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 6/20 | 0.50 |
| ▸ | HTT | P42858 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | XBP1 | P17861 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 4/20 | 0.43 |
| ▸ | MMP2 | P08253 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.42 |
| ▸ | MMP9 | P14780 | 3/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4027206 | 0.98 | MMP1 (0.49) | MMP1HTTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL7657519 | 0.90 | HTT (0.44) | MMP1HTTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL433497 | 0.89 | HTT (0.58) | HTTALDH1A1LMNASMN1; SMN2HSD17B10 | |
| SCHEMBL9720036 | 0.89 | HTT (0.58) | HTTALDH1A1LMNASMN1; SMN2HSD17B10 | |
| SCHEMBL7512941 | 0.82 | PTGS2 (0.55) | MMP1HTTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL6338957 | 0.82 | MMP1 (0.53) | MMP1HTTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL9536733 | 0.81 | SOS1 (0.64) | MMP1HTTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL1133769 | 0.81 | PGR (0.53) | MMP1HTTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL31244 | 0.81 | SOS1 (0.64) | MMP1HTTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL2845658 | 0.80 | LMNA (0.55) | MMP1HTTALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170081278-A1 | Novel compounds | GLAXO GROUP LIMITED (GB) | 2017-03-23 | — | — | US | disclosed |
| US-20170081278-A1 | Novel compounds | GLAXO GROUP LIMITED (GB) | 2017-03-23 | — | — | US | disclosed |
| US-9540318-B2 | Sulfonamide compounds and their use in the modulation retinoid-related orphan receptor | GLAXO GROUP LIMITED (GB) | 2017-01-10 | — | — | US | disclosed |
| US-9540318-B2 | Sulfonamide compounds and their use in the modulation retinoid-related orphan receptor | GLAXO GROUP LIMITED (GB) | 2017-01-10 | — | — | US | disclosed |
| US-20150361039-A1 | SULFONAMIDE COMPOUNDS AND THEIR USE IN THE MODULATION RETINOID-RELATED ORPHAN RECEPTOR | GLAXO GROUP LIMITED (GB) | 2015-12-17 | — | — | US | disclosed |
| US-20150361039-A1 | SULFONAMIDE COMPOUNDS AND THEIR USE IN THE MODULATION RETINOID-RELATED ORPHAN RECEPTOR | GLAXO GROUP LIMITED (GB) | 2015-12-17 | — | — | US | disclosed |
| US-9150508-B2 | Sulfonamide compounds and their use in the modulation retinoid-related orphan receptor | GLAXO GROUP LIMITED (GB) | 2015-10-06 | — | — | US | disclosed |
| US-9150508-B2 | Sulfonamide compounds and their use in the modulation retinoid-related orphan receptor | GLAXO GROUP LIMITED (GB) | 2015-10-06 | — | — | US | disclosed |
| US-20140243362-A1 | SULFONAMIDE COMPOUNDS AND THEIR USE IN THE MODULATION RETINOID-RELATED ORPHAN RECEPTOR | GLAXO GROUP LIMITED (GB) | 2014-08-28 | — | — | US | disclosed |
| US-20140243362-A1 | SULFONAMIDE COMPOUNDS AND THEIR USE IN THE MODULATION RETINOID-RELATED ORPHAN RECEPTOR | GLAXO GROUP LIMITED (GB) | 2014-08-28 | — | — | US | disclosed |
| EP-1144369-A2 | ACETYLENIC ARYL SULFONAMIDE AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS | American Cyanamid Company (US) | 2001-10-17 | — | — | EP | disclosed |
| US-6277885-B1 | INHIBITORS OF TUMOR NECROSIS FACTOR-ALPHA CONVERTING ENZYME | AMERICAN CYANAMID COMPANY | 2001-08-21 | — | — | US | disclosed |
| EP-1069110-A1 | SULFONAMIDE DERIVATIVES | Sankyo Company Limited (JP) | 2001-01-17 | — | — | EP | disclosed |
| EP-1051407-A1 | 2,3,4,5-TETRAHYDRO-1H-[1,4]-BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | American Cyanamid Company (US) | 2000-11-15 | — | — | EP | disclosed |
| WO-2000044712-A1 | N-HYDROXYFORMAMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | ABBOTT LABORATORIES (US) | 2000-08-03 | — | — | WO | disclosed |
| WO-2000044710-A2 | ACETYLENIC ARYL SULFONAMIDE AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
| US-6071903-A | ENZYME INHIBITORS OF MATRIX METALLOPROTEINASES (MMPS); ANTITUMOR,-CARCINOGENIC AND -ARTHRITIC AGENTS; OSTEOARTHRITIS; RHEUMATOID DISEASES; DEGENERATIVE CARTILAGE LOSS; LONG-ACTING, ORALLY BIOAVAILABLE NONPEPTIDE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-06-06 | — | — | US | disclosed |
| US-6066633-A | PREVENT TISSUE DEGRADATION | ADIR ET COMPAGNIE (FR) | 2000-05-23 | — | — | US | disclosed |
| WO-1999037625-A1 | 2,3,4,5-TETRAHYDRO-1H-[1,4]-BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1999-07-29 | — | — | WO | disclosed |
| CN-1217332-A | Metal protease inhibitor, preparation method therefor and medicinal composition containing same | ADIR (FR) | 1999-05-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081278-A1 | Novel compounds | RORC, RORB, RORA | MMP1 4804/4885HTT 4500/4885ALDH1A1 913/4885 |
| US-20150361039-A1 | SULFONAMIDE COMPOUNDS AND THEIR USE IN THE MODULATION RETINOID-RELATED ORPHAN RECEPTOR | RORA, RORC, RORB | MMP1 4783/4885HTT 4305/4885ALDH1A1 940/4885 |
| US-20140243362-A1 | SULFONAMIDE COMPOUNDS AND THEIR USE IN THE MODULATION RETINOID-RELATED ORPHAN RECEPTOR | RORA, RORB, RORC | MMP1 4753/4885HTT 4649/4885ALDH1A1 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.